BCLI - ブレインスト―ム・セル・セラピュ―ティクス （Brainstorm Cell Therapeutics Inc.） ブレインスト―ム・セル・セラピュ―ティクスBCLIのチャート
BCLIの企業情報
| symbol | BCLI |
|---|---|
| 会社名 | Brainstorm Cell Therapeutics Inc （ブレインスト―ム・セル・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS also known as Lou Gehrig's disease) Multiple Sclerosis (MS) and Parkinson's disease (PD) among others. Its subsidiary Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary) holds rights to commercialize the technology NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial. ブレインスト―ム・セル・セラピュ―ティクスは、米国のバイオテクノロジ―会社。筋萎縮性側索硬化症(ル―・ゲ―リック病としても知られている)、多発性硬化症、およびパ―キンソン病などの神経変性疾患を衰弱させるための成体幹細胞治療を開発する。「NurOwn」は、同社独自のプロセスで、神経変性疾患を治療するために設計されている。 brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr |
| 本社所在地 | 1325 Avenue of Americas 28th Floor New York NY 10019 USA |
| 代表者氏名 | Irit Arbel Irit Arbel |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 201-488-0460 |
| 設立年月日 | 36770 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 24人 |
| url | www.brainstorm-cell.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bcli |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.44100 |
| 終値（lastsale） | 3.62 |
| 時価総額（marketcap） | 74823691.36 |
| 時価総額 | 時価総額（百万ドル） 75.44378 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 58.00478 |
| 当期純利益 | 当期純利益（百万ドル） -7.51600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss increased 91% to $5.4M. Higher net loss reflects General and administrative - Balancing v increase of 93% to $2.6M (expense) Research and development - Balancing val increase of 85% to $2.4M (expense) Stock-based Compensation in SGA increase from $108K to $315K (expense). |
BCLIのテクニカル分析
BCLIのニュース
Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2023 Earnings Call Transcript 2023/05/15 14:27:07 Seeking Alpha
Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ETCompany ParticipantsMichael Wood - LifeSci AdvisorsChaim Lebovits - President…
BrainStorm Cell Therapeutics GAAP EPS of -$0.14 beats by $0.03 2023/05/15 11:13:08 Seeking Alpha
BrainStorm Cell Therapeutics press release (BCLI): Q1 GAAP EPS of -$0.14 beats by $0.03.Cash, cash equivalents, and short-term bank deposits were approximately $2.2M as of March…
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update 2023/05/15 11:05:00 PR Newswire
Biologics License Application for NurOwn for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, May 15, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading…
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update 2023/05/15 11:05:00 Finanz Nachrichten
Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK,…
Earnings Scheduled For May 15, 2023 2023/05/15 09:32:35 Benzinga
Companies Reporting Before The Bell • Caledonia Mining (AMEX: CMCL ) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ: SOHU ) is projected to report earnings for its first quarter. • Modiv (NYSE: MDV ) is estimated to report earnings for its first quarter. • LM Funding America (NASDAQ: LMFA ) is estimated to report quarterly loss at $0.48 per share on revenue of $1.40 million. • Sachem Cap (AMEX: SACH ) is projected to report quarterly earnings at $0.13 per share on revenue of $14.72 million. • Lifeway Foods (NASDAQ: LWAY ) is likely to report quarterly earnings at $0.08 per share on revenue of $36.00 million. • iSun (NASDAQ: ISUN ) is expected to report quarterly loss at $0.20 per share on revenue of $19.78 million. • Carlyle Group (NASDAQ: CG ) is likely to report quarterly loss at $0.09 per share on revenue of $221.89 million. • Azul (NYSE: AZUL ) is projected to report quarterly loss at $0.34 per share on revenue of $932.13 million. • Brainstorm Cell (NASDAQ: BCLI ) is projected to report earnings for its first quarter.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Price Target Raised to $10.00 at Maxim Group 2023/04/02 06:37:37 The AM Reporter
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) had its target price hoisted by equities researchers at Maxim Group from $5.00 to $10.00 in a research report issued on Friday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 203.03% […]
BCLI, SOUN and IPDN among mid-day movers 2023/03/31 16:58:15 Seeking Alpha
Gainers: Y-mAbs Therapeutics YMAB +61%.Burford Capital Limited BUR +42%.Pulse Biosciences PLSE +29%.Brainstorm Cell Therapeutics (BCLI) +29%.Bionomics Limited (BNOX)…
Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2022 Earnings Call Transcript 2023/03/30 15:36:09 Seeking Alpha
Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsMichael Wood - LifeSci AdvisorsChaim Lebovits -…
Brainstorm stock pares off gains amid FY22 results seeing cash decline 2023/03/30 15:29:30 Seeking Alpha
Brainstorm Cell Therapeutics (BCLI) stock fell ~10% amid FY22 results after soaring ~50% in the past three days. Read more here
Earnings Scheduled For March 30, 2023 2023/03/30 11:24:25 Benzinga
Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.
Boom Or Bust: What Is Next For Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Stock? 2022/09/10 20:00:00 Marketing Sentinel
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting -0.10. At the close of trading, the stock’s price was $3.80, to imply an increase of 12.09% or $0.41 in intraday trading. The BCLI share’s 52-week high remains $4.70, putting it -23.68% down since … Boom Or Bust: What Is Next For Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Stock? Read More »
Investing in Brainstorm Cell Therapeutics Inc. (BCLI) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/09/05 13:08:00 US Post News
In Friday’s session, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) marked $3.35 per share, down from $3.40 in the previous session. While Brainstorm Cell Therapeutics Inc. has underperformed by -1.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCLI fell by -5.37%, with highs and lows ranging from […]
Brainstorm Cell Therapeutics: Upcoming BLA In ALS (NASDAQ:BCLI) 2022/08/21 07:57:56 Seeking Alpha
Brainstorm is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. Read why I am rating BCLI stock as a buy.